经肝动脉栓塞联合化疗治疗原发性肝癌的疗效观察

Effect Observation of Transcatheter Arterial Chemoembolization Combined with Chemotherapy on Primary Liver Cancer

目的探索经肝动脉栓塞联合化疗治疗原发性肝癌的疗效。方法选取2016年10月23日至2017年10月23日我院原发性肝癌100例患者(实施信封随机分组模式),对照组的50例患者进行化疗干预,观察组的50例患者进行经肝动脉栓塞联合化疗干预。结果观察组患者的总有效率(96.00%)、不良反应发生率(4.00%)、生存时间(21.85±5.94)个月、6个月生存率(94.00%)、12个月生存率(76.00%)、24个月生存率(60.00%)均优于对照组(P<0.05)。结论对原发性肝癌患者实施经肝动脉栓塞联合化疗干预效果显著。

Objective to explore effect of transcatheter arterial chemoembolization combined with chemotherapy in treatment of primary liver cancer. Methods choose 100 cases primary liver cancer patients in our hospital from October 23, 2016 to October 23, 2017, with random packet grouping mode, 50 cases in control group were treated with chemotherapy, and 50 in observation group with transcatheter arterial embolization combined with chemotherapy. Results total effective rate（96%）, adverse reaction incidence（4%）, survival time（21.85±5.94）, 6 months survival rate（94%）, 12 month survival rate（76%）, and 24 months survival rate（60%） was better than control group（P0.05）. Conclusion transcatheter arterial chemoembolization combined with chemotherapy has significant effect in treatment of primary liver cancer patients.